立方制药(003020.SZ)：收到药品注册受理通知书

Core Viewpoint - The company, Lifan Pharmaceutical, has received the acceptance notice for the drug registration application of Dapagliflozin Metformin Extended-Release Tablets from the National Medical Products Administration, indicating progress in bringing this combination diabetes medication to market [1] Group 1: Product Details - Dapagliflozin Metformin Extended-Release Tablets are a fixed-dose combination formulation that includes the SGLT2 inhibitor Dapagliflozin and the biguanide Metformin, which work synergistically to control blood sugar levels [1] - Dapagliflozin lowers blood sugar by promoting urinary glucose excretion, while Metformin primarily reduces hepatic glucose output and improves insulin sensitivity [1] - This combination aims to provide more comprehensive and effective blood sugar control for adult patients with type 2 diabetes [1] Group 2: Market Context - The product is co-developed by Bristol-Myers Squibb and AstraZeneca, highlighting collaboration between major pharmaceutical companies in the diabetes treatment space [1] - As of the announcement date, there are eight domestic companies that have received approval for similar products, indicating a competitive market landscape for diabetes medications in China [1]